A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition.
Publication
, Conference
Levis, M; Smith, BD; Beran, M; Baer, MR; Erba, HP; Cripe, L; Coutre, S; Advani, A; Perl, A; Devetten, M; Stuart, R; Tallman, MS; Brown, P ...
Published in: BLOOD
November 16, 2005
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2005
Volume
106
Issue
11
Start / End Page
121A / 121A
Location
Atlanta, GA
Publisher
AMER SOC HEMATOLOGY
Conference Name
47th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Levis, M., Smith, B. D., Beran, M., Baer, M. R., Erba, H. P., Cripe, L., … Small, D. (2005). A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition. In BLOOD (Vol. 106, pp. 121A-121A). Atlanta, GA: AMER SOC HEMATOLOGY.
Levis, M., B. D. Smith, M. Beran, M. R. Baer, H. P. Erba, L. Cripe, S. Coutre, et al. “A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition.” In BLOOD, 106:121A-121A. AMER SOC HEMATOLOGY, 2005.
Levis M, Smith BD, Beran M, Baer MR, Erba HP, Cripe L, et al. A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition. In: BLOOD. AMER SOC HEMATOLOGY; 2005. p. 121A-121A.
Levis, M., et al. “A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition.” BLOOD, vol. 106, no. 11, AMER SOC HEMATOLOGY, 2005, pp. 121A-121A.
Levis M, Smith BD, Beran M, Baer MR, Erba HP, Cripe L, Coutre S, Advani A, Perl A, Devetten M, Stuart R, Tallman MS, Brown P, Tremmel L, Small D. A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition. BLOOD. AMER SOC HEMATOLOGY; 2005. p. 121A-121A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2005
Volume
106
Issue
11
Start / End Page
121A / 121A
Location
Atlanta, GA
Publisher
AMER SOC HEMATOLOGY
Conference Name
47th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology